Literature DB >> 9374563

Renal function after short-term ibuprofen use in infants and children.

S M Lesko1, A A Mitchell.   

Abstract

OBJECTIVE: To test the hypothesis that short-term use of ibuprofen increases the risk of impaired renal function in children. STUDY
DESIGN: Randomized, double-blind acetaminophen-controlled clinical trial. Children with a febrile illness were enrolled from outpatient pediatric and family medicine practices and randomly assigned to receive either acetaminophen suspension or one of two dosages of ibuprofen suspension (5 mg/kg or 10 mg/kg) for fever control.
RESULTS: Mean blood urea nitrogen levels on admission among children admitted to hospital and assigned ibuprofen 5 mg/kg (n = 96), ibuprofen 10 mg/kg (n = 102), and acetaminophen 12 mg/kg (n = 87) were 4.1, 3.8, and 3.9 mmol/L, respectively. The corresponding creatinine levels were 43, 41, and 43 micromol/L, respectively. The prevalence of a creatinine level >62 micromol/L was 9.5% overall and did not vary by antipyretic assignment. Among 83 children hospitalized with dehydration, the mean creatinine level was 44 micromol/L, and the prevalence of an elevated creatinine was 14%; neither measure varied by antipyretic assignment.
CONCLUSION: Although renal failure in children has been reported after ibuprofen use, these data suggest that for short-term use the risk of less severe renal impairment, as reflected by blood urea nitrogen and creatinine levels, is small and not significantly greater than that after acetaminophen use.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9374563     DOI: 10.1542/peds.100.6.954

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  25 in total

Review 1.  Risks and benefits of nonsteroidal anti-inflammatory drugs in children: a comparison with paracetamol.

Authors:  C Litalien; E Jacqz-Aigrain
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 2.  Non-steroidal anti-inflammatory drugs (NSAIDs) for chronic non-cancer pain in children and adolescents.

Authors:  Christopher Eccleston; Tess E Cooper; Emma Fisher; Brian Anderson; Nick Mr Wilkinson
Journal:  Cochrane Database Syst Rev       Date:  2017-08-02

Review 3.  Non-steroidal anti-inflammatory drugs (NSAIDs) for cancer-related pain in children and adolescents.

Authors:  Tess E Cooper; Lauren C Heathcote; Brian Anderson; Marie-Claude Grégoire; Gustaf Ljungman; Christopher Eccleston
Journal:  Cochrane Database Syst Rev       Date:  2017-07-24

4.  Albuminuria and tubular markers in juvenile idiopathic arthritis.

Authors:  Ayla Kamburoğlu Göksel; Lale Sever; Ozgür Kasapçopur; Salim Calişkan; Huriye Balci; Nil Arisoy
Journal:  Pediatr Nephrol       Date:  2004-12-15       Impact factor: 3.714

5.  Ibuprofen-associated acute kidney injury in dehydrated children with acute gastroenteritis.

Authors:  Alejandro Balestracci; Mauricio Ezquer; María Eugenia Elmo; Andrea Molini; Claudia Thorel; Milagros Torrents; Ismael Toledo
Journal:  Pediatr Nephrol       Date:  2015-04-21       Impact factor: 3.714

Review 6.  Efficacy and Safety of Ibuprofen in Infants Aged Between 3 and 6 Months.

Authors:  Victoria C Ziesenitz; Andreas Zutter; Thomas O Erb; Johannes N van den Anker
Journal:  Paediatr Drugs       Date:  2017-08       Impact factor: 3.022

7.  [Pediatric perioperative systemic pain therapy: Austrian interdisciplinary recommendations on pediatric perioperative pain management].

Authors:  B Messerer; G Grögl; W Stromer; W Jaksch
Journal:  Schmerz       Date:  2014-02       Impact factor: 1.107

Review 8.  Ibuprofen: pharmacology, efficacy and safety.

Authors:  K D Rainsford
Journal:  Inflammopharmacology       Date:  2009-11-21       Impact factor: 4.473

Review 9.  Paracetamol for treating fever in children.

Authors:  M Meremikwu; A Oyo-Ita
Journal:  Cochrane Database Syst Rev       Date:  2002

Review 10.  Nonsteroidal anti-inflammatory agents in neonates.

Authors:  John L Morris; David A Rosen; Kathleen R Rosen
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.